Servicio de Endocrinología y Nutrición, Hospital Universitario Virgen Macarena, Seville, Spain.
Front Endocrinol (Lausanne). 2024 Jun 4;15:1386542. doi: 10.3389/fendo.2024.1386542. eCollection 2024.
Glucagon-like peptide-1 receptor-agonists (GLP-1ra), such as semaglutide, have emerged as promising treatments, demonstrating sustained weight reduction and metabolic benefits. This study aims to assess the impact of oral and subcutaneous semaglutide on body composition and metabolic parameters in patients with T2DM and obesity.
A 24-week quasi-experimental retrospective study including adults with T2DM and obesity (BMI ≥ 30 kg/m²) who were treated with either daily-oral or weekly-subcutaneous semaglutide. Body composition was measured using bioelectrical impedance analysis, evaluating fat mass, fat-free mass, total body water, skeletal muscle mass, and whole-body phase angle. Analytical parameters included lipid profile and glycaemic control. Statistical analyses were performed using SPSS v.26.
Participants (n=88) experienced significant weight loss after treatment with semaglutide (9.5% in subcutaneous, 9.4% in oral, P<0.001). Weight reduction primarily resulted from fat mass reduction without substantial lean mass compromise. Visceral fat area decreased, whiles phase-angle remained stable. Improvements in lipid profiles and glycaemic control were observed, with a decrease in both HbA1c and insulin requirements. Multivariate analysis demonstrated comparable impacts of oral and subcutaneous semaglutide on body composition.
Semaglutide, administered orally or subcutaneously, demonstrated positive effects on body composition, metabolic and glycaemic control in patients with T2DM and obesity. This real-world study highlights the potential of bioelectrical impedance analysis in assessing antidiabetic drugs' impact on body composition, providing valuable insights for future research and clinical applications.
胰高血糖素样肽-1 受体激动剂（GLP-1ra），如司美格鲁肽，已成为有前途的治疗方法，具有持续的体重减轻和代谢益处。本研究旨在评估口服和皮下司美格鲁肽对 T2DM 和肥胖患者的身体成分和代谢参数的影响。
一项为期 24 周的准实验性回顾性研究，纳入接受每日口服或每周皮下司美格鲁肽治疗的 T2DM 和肥胖（BMI≥30kg/m²）成年人。使用生物电阻抗分析测量身体成分，评估脂肪量、去脂体重、总体液、骨骼肌量和全身相位角。分析参数包括血脂谱和血糖控制。使用 SPSS v.26 进行统计分析。
接受司美格鲁肽治疗后，参与者（n=88）体重显著减轻（皮下组 9.5%，口服组 9.4%，P<0.001）。体重减轻主要是由于脂肪量减少，而瘦体重没有明显减少。内脏脂肪面积减少，而相位角保持稳定。血脂谱和血糖控制得到改善，HbA1c 和胰岛素需求均降低。多变量分析表明，口服和皮下司美格鲁肽对身体成分的影响相当。
在 T2DM 和肥胖患者中，口服和皮下给予司美格鲁肽均可对身体成分、代谢和血糖控制产生积极影响。本真实世界研究强调了生物电阻抗分析在评估抗糖尿病药物对身体成分影响方面的潜力，为未来的研究和临床应用提供了有价值的见解。
